GIP; GLP-1 and glucagon receptor tri-agonist
Retatrutide 12 mg subcutaneous once weekly
RETA_SC_12MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -11.93 (-18.27 to -5.29) | 0.99 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -9.57 (-15.33 to -3.73) | 0.96 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.84 (0.13 to 3.88) | 0.55 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.42 (1.28 to 9.24) | 0.40 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.20 (0.84 to 11.39) | 0.44 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.02 (0.81 to 10.90) | 0.29 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -15.39 (-20.48 to -7.46) | 0.94 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -21.07 (-26.96 to -10.14) | 0.84 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.72 (0.10 to 3.98) | 0.63 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.61 (2.10 to 10.69) | 0.37 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.73 (2.10 to 35.75) | 0.30 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.26 (0.45 to 3.63) | 0.66 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.37 (1.24 to 18.26) | 0.23 |
Trials
- NCT04867785A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes2021 · 281 randomized · 36 weeks
- NCT04881760A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities2021 · 338 randomized · 48 weeks